Pear Therapeutics Announces New Analysis Showing Reduction in Healthcare Resource Utilization and Associated Costs in Patients Using reSET® at Six Months

Pear Therapeutics Announces New Analysis Showing Reduction in Healthcare Resource Utilization and Associated Costs in Patients Using reSET® at Six Months
CANNANNEW REPORT

reSET® is the only FDA-authorized prescription digital therapeutic (PDT) for the treatment of substance use disorder (SUD), including alcohol, cannabis, cocaine, and stimulants Results support the real-world value of reSET, demonstrating durable treatment outcomes and reductions in healthcare resource utilization 6-month analysis is the first ever describing real-world health economic outcomes in patients undergoing treatment for multiple substance use disorders, and who were treated with reSET, demonstrating a 50% reduction in hospital encounters and >$3,500 per patient cost savings1 BOSTON–(BUSINESS WIRE)–Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs), today announced a manuscript accepted for publication and available via pre-print of a real-world study demonstrating reduced resource utilization and associated costs for reSET®, the only FDA-authorized PDT for the treatment of substance use disorder (SUD), including alcohol, cannabis, cocaine, and stimulants. Results from a real-world study of reSET showed a statistically significant reduction in overall hospital encounters and an estimated $3,591 reduction in per-patient costs in the six months after reSET initiation compared to a 6-month pre-reSET baseline. This health economic study was accepted for publication and made available via pre-print by the international peer-reviewed journal Advances in Therapy.1 “Pear now has a continuum of evidence supporting our three FDA-authorized prescription digital therapeutics, including randomized controlled trials, real-world clinical data, and real-world health economic data,” said Yuri Maricich, M.D., Chief Medical Officer and Head of Development at Pear Therapeutics. “This new study suggests a longer-term durability of outcomes for patients with substance use disorder, while also a reduction in the use of more costly health care resources in the first 6 months. As we strive to provide additional, flexible, and remote approaches to treatment for these patients and their communities, it’s increasingly critical to understand the effectiveness, durability, and value PDTs…

Excerpt only …
READ MORE BELOW
Source : Pear Therapeutics Announces New Analysis Showing Reduction in Healthcare Resource Utilization and Associated Costs in Patients Using reSET® at Six Months

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.